Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Schutz FA, Park SH, Nosov DA, Porta C, Lee JL, Garcia-Del-Muro X, Biscaldi E, Manneh Kopp R, Oya M, He L, Wang A, Perini RF, Vickery D, Albiges L, Rini B; LITESPARK-005 Investigators. Choueiri TK, et al. Among authors: stadler wm. N Engl J Med. 2024 Aug 22;391(8):710-721. doi: 10.1056/NEJMoa2313906. N Engl J Med. 2024. PMID: 39167807 Clinical Trial.
Optimizing the doses of cancer drugs after usual dose finding.
Strohbehn GW, Stadler WM, Boonstra PS, Ratain MJ. Strohbehn GW, et al. Among authors: stadler wm. Clin Trials. 2024 Jun;21(3):340-349. doi: 10.1177/17407745231213882. Epub 2023 Dec 27. Clin Trials. 2024. PMID: 38148731
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma.
Huang D, Lynch C, Serra LM, Sweis RF, Chang PJ, Stadler WM, Szmulewitz RZ, O'Donnell PH, Sidana A, Eggener SE, Shalhav AL, Liauw SL, Pitroda SP. Huang D, et al. Among authors: stadler wm. Clin Transl Radiat Oncol. 2024 Oct 28;49:100879. doi: 10.1016/j.ctro.2024.100879. eCollection 2024 Nov. Clin Transl Radiat Oncol. 2024. PMID: 39529961 Free PMC article.
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.
Berg SA, La Rosa S, Zhang T, Pierorazio PM, Albiges L, Beckermann KE, Campbell MT, Carlo MI, Coleman K, George DJ, Geynisman DM, Johnson R, Jonasch E, Maranchie JK, McGregor BA, Shapiro DD, Singer EA, Shuch BM, Stadler WM, Tannir NM, Zakharia Y, Vaishampayan UN, Thall PF, Msaouel P. Berg SA, et al. Among authors: stadler wm. Urol Oncol. 2024 Nov 4:S1078-1439(24)00701-4. doi: 10.1016/j.urolonc.2024.10.022. Online ahead of print. Urol Oncol. 2024. PMID: 39500687 Free article. Review.
Feasibility of structuring electronic health record data to facilitate real-world data research: ICAREdata methods applied to multicenter cancer clinical trials.
George S, Campbell N, Hillman SL, Harlos ES, Stein DWJ, Chan MY, Chow SL, Elrahi CL, Quina AC, Kokolus MC, Casagni MD, Weiss M, Anderson DM, Stadler WM, Hoff OC, Rivera DR, Kluetz PG, Mandrekar SJ, Piantadosi S. George S, et al. Among authors: stadler wm. Cancer. 2024 Aug 28. doi: 10.1002/cncr.35528. Online ahead of print. Cancer. 2024. PMID: 39192753
Bladder-Preserving Trimodality Therapy With Capecitabine.
Lynch C, Sweis RF, Modi P, Agarwal PK, Szmulewitz RZ, Stadler WM, O'Donnell PH, Liauw SL, Pitroda SP. Lynch C, et al. Among authors: stadler wm. Clin Genitourin Cancer. 2024 Apr;22(2):476-482.e1. doi: 10.1016/j.clgc.2024.01.002. Epub 2024 Jan 9. Clin Genitourin Cancer. 2024. PMID: 38228414
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
Paller CJ, Barata PC, Lorentz J, Appleman LJ, Armstrong AJ, DeMarco TA, Dreicer R, Elrod JAB, Fleming M, George C, Heath EI, Hussain MHA, Mao S, McKay RR, Morgans AK, Orton M, Pili R, Riedel E, Saraiya B, Sigmond J, Sokolova A, Stadler WM, Tran C, Macario N, Vinson J, Green R, Cheng HH; PROMISE Trial Investigators. Paller CJ, et al. Among authors: stadler wm. Prostate. 2024 Feb;84(3):292-302. doi: 10.1002/pros.24650. Epub 2023 Nov 14. Prostate. 2024. PMID: 37964482
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
Rosenberg AJ, Liao CY, Karrison T, de Souza JA, Worden FP, Libao B, Krzyzanowska MK, Hayes DN, Winquist E, Saloura V, Prescott K, Villaflor VM, Seiwert TY, Schechter RB, Stadler WM, Cohen EEW, Vokes EE. Rosenberg AJ, et al. Among authors: stadler wm. Ann Oncol. 2023 Aug;34(8):714-722. doi: 10.1016/j.annonc.2023.05.002. Epub 2023 May 13. Ann Oncol. 2023. PMID: 37182801 Free PMC article. Clinical Trial.
304 results